Safety and Efficacy Study of Bimosiamose Cream to Treat Psoriasis
NCT ID: NCT00823693
Last Updated: 2009-08-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
107 participants
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis
NCT02969018
Study Comparing AM001 Cream to Vehicle in the Treatment of Plaque Psoriasis
NCT01938599
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis
NCT01815424
Efficacy and Safety of ME3183 in Subjects With Moderate to Severe Plaque Psoriasis
NCT05268016
Safety and Efficacy Study of a Novel Ointment to Treat Plaque Type Psoriasis
NCT01029405
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bimosiamose Cream
Bimosiamose Cream
Placebo Cream
Placebo Cream
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bimosiamose Cream
Placebo Cream
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least 18 years of age
* Written informed consent
Exclusion Criteria
* More than 20% Body Surface Area (BSA) affected by psoriasis
* Use of certain anti-psoriasis medication or treatments
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Revotar Biopharmaceuticals AG
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Charité Campus Mitte, Klinik für Dermatologie, Venerologie und Allergologie
Berlin, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R013
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.